FDA Orphan Drug Designation
EMA COMP Positive Opinion
Engineering Exosomes to Target Tumors.
Exousia Bio, Inc. is a U.S. biotechnology company advancing next-generation exosome-based cancer therapeutics through strategic technology partnerships and collaborations. We are developing innovative, targeted biotherapeutics for difficult-to-treat malignancies, including glioblastoma.
Our Pipeline
Targeting Treatment-Resistant Cells.
EXO-NG01 is an engineered exosome designed to deliver shRNA targeting NANOG mRNA into glioblastoma cells. By downregulating NANOG expression, it targets cancer stemness and treatment resistance — with the goal of enhancing tumor sensitivity to temozolomide.
Our science
A Platform, Not a Drug.
Engineered exosomes act as targeted biological delivery vehicles for nucleic acid medicines — shRNA, siRNA, and DNA. Brain-homing peptide engineering is designed to carry that cargo across the blood-brain barrier to difficult-to-treat tumors.
Latest Updates
Regulatory
FDA grants Orphan Drug Designation for malignant glioma
Designation covers shRNA targeting NANONG mRNA. It does not constitute FDA approval.
Europe
EMA COMP issues a positive opinion
A positive opinion from the Committee for Orphan Medicinal Products extends the regulatory frame to the EU.
Access
A framework for physician-initiated expanded access
Exousia Bio is developing a review pathway for compassionate use requests in mlignant glioma.
Company updates, in your inbox.
Regulatory milestones, preclinical progress, and expanded access news for investors, analysts, and treating physicians.